Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss
Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss
It is doubtless a positive to see that the Precigen, Inc. (NASDAQ:PGEN) share price has gained some 41% in the last three months. But that doesn't change the fact that the returns over the last three years have been stomach churning. Indeed, the share price is down a whopping 83% in the last three years. So it sure is nice to see a bit of an improvement. The thing to think about is whether the business has really turned around. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
Precigen公司(纳斯达克股票代码:PGEN)的股价在过去三个月中上涨了约41%,这无疑是一个积极因素。但这并不能改变过去三年的回报令人大跌眼镜的事实。事实上,股价在过去三年中下跌了83%。因此,看到一点改进肯定是件好事。要考虑的是业务是否真的发生了转机。我们真的希望任何在价格暴跌中坚持下去的人都能拥有多元化的投资组合。即使你赔了钱,你也不必输掉教训。
While the last three years has been tough for Precigen shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
尽管过去三年对Precigen的股东来说是艰难的,但上周显示出希望的迹象。因此,让我们来看看长期基本面,看看它们是否是负回报的驱动力。
View our latest analysis for Precigen
查看我们对 Precigen 的最新分析
Given that Precigen didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
鉴于Precigen在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。一般而言,没有利润的公司预计每年收入将增长,而且速度很快。那是因为如果收入增长可以忽略不计,而且从来没有盈利,就很难确信一家公司能否实现可持续发展。
Over the last three years, Precigen's revenue dropped 58% per year. That's definitely a weaker result than most pre-profit companies report. The swift share price decline at an annual compound rate of 22%, reflects this weak fundamental performance. Never forget that loss making companies with falling revenue can and do cause losses for everyday investors. It's worth remembering that investors call buying a steeply falling share price 'catching a falling knife' because it is a dangerous pass time.
在过去的三年中,Precigen的收入每年下降58%。这绝对比大多数盈利前公司报告的结果要差。股价以22%的年复合率迅速下跌,反映了这种疲软的基本面表现。永远不要忘记,收入下降的亏损公司可能会而且确实会给普通投资者造成损失。值得记住的是,投资者称买入急剧下跌的股价是 “抓住一把下跌的刀子”,因为这是一个危险的消磨时间。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240126/0-43251658a783abd8414fb7e777c27650-0-f530e7a32a70c8c79f2283880fc41c14.png/big)
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Precigen stock, you should check out this free report showing analyst profit forecasts.
像我们一样,内部人士在过去的十二个月中一直在购买股票。话虽如此,大多数人认为收益和收入增长趋势是更有意义的业务指南。如果您正在考虑买入或卖出Precigen股票,则应查看这份显示分析师利润预测的免费报告。
A Different Perspective
不同的视角
Precigen shareholders are down 12% for the year, but the market itself is up 20%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 13% per annum loss investors have suffered over the last half decade. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Precigen , and understanding them should be part of your investment process.
Precigen的股东今年下跌了12%,但市场本身却上涨了20%。即使是优质股票的股价有时也会下跌,但我们希望在过于感兴趣之前看到企业基本指标的改善。但是,去年的亏损并不像投资者在过去五年中遭受的每年13%的亏损那么严重。我们需要看到关键指标的持续改善,然后才能激起极大的热情。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,投资风险的幽灵无处不在。我们已经向Precigen确定了两个警告信号,了解它们应该是您投资过程的一部分。
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
还有很多其他公司有内部人士购买股票。你可能不想错过这份业内人士正在收购的成长型公司的免费名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。